Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
No direct coverage yet · Showing articles that mention DNTH
GlobeNewswire Inc.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dianthus Therapeutics announced the grant of equity awards to three newly-hired, non-executive employees on November 2, 2026. The inducement grants consist of non-qualified stock options to purchase 26,000 shares of common stock with an exercise price of $82.25 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.
Zacks Investment Research
Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesRegeneron reported Q3 2026 earnings of $20.07 per share, beating consensus estimates of $16.08 by 24.81%, with revenues of $5.12 billion exceeding expectations by 12.43%. The stock has underperformed the S&P 500 year-to-date, gaining 6.1% versus the market's 12.8%.
Regeneron holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Dianthus Therapeutics is expected to report a quarterly loss of $1.00 per share with revenues of $0.7 million.
Headlines open the publisher's site.
